Navigation Links
LeMaitre Vascular Reports Q4 2007 Revenue of $11.1 Million, a 27% Increase
Date:3/4/2008

BURLINGTON, Mass., March 4 /PRNewswire-FirstCall/ -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of peripheral vascular devices and implants, today announced financial results for Q4 2007 and the year ended December 31, 2007. Q4 2007 revenues were $11.1 million, an increase of 27% over Q4 2006. 2007 revenues were $41.4 million, an increase of 20% over 2006.

Q4 2007 revenues increased 52% in the Company's endovascular and dialysis access category, 17% in its vascular category, and 13% in the general surgery category. For the full year 2007, the Company's endovascular and dialysis access category increased 44%, while the vascular and general surgery categories grew 12% and 2%, respectively. The principal sales drivers in 2007 were the expansion of the sales force, the first year of European distribution of the Endologix stent graft, the weak dollar, and higher average selling prices.

For Q4 2007, the Company reported a gross margin of 73.3% versus 75.3% in the year earlier quarter. This decrease was primarily due to a $105,000 non- cash charge related to OEM inventory included in the December 2007 Biomateriali acquisition. The Company's 2007 gross margin was 74.1% versus 72.9% in 2006. The annual gross margin improvement was primarily driven by price increases and manufacturing cost reductions.

The Company ended 2007 with $22.9 million in cash and cash equivalents. This compares to $25.6 million in cash and cash equivalents at the end of Q3 2007. $2.4 million of this $2.7 million reduction was attributable to the acquisitions executed in Q4 2007.

George W. LeMaitre, Chairman and CEO said, "We had a successful 2007. We grew sales by 20% and posted a record 74.1% gross margin. We also completed four acquisit Total liabilities 12,565 6,264

Stockholders' equity

Preferred stock - -

Common stock 156 153

Additional paid-in capital 61,186 60,504

Accumulated deficit (12,880) (9,946)

Accumulated other comprehensive

income 291 73

Treasury stock (167) (85)

Total stockholders' equity 48,586 50,699

Total liabilities and stockholders'

equity $61,151 $56,963

LEMAITRE VASCULAR, INC (Nasdaq: LMAT)

SELECTED NET SALES INFORMATION

(amounts in thousands)

(unaudited)

For the three months ended

December 31, 2007 December 31, 2006

$ % $ %

Net Sales by Product Category:

Endovascular & Dialysis $3,910 35% $2,573 30%

Vascular 6,181 56% 5,290 60%

General Surgery 1,013 9% 894 10%

Total net sales $11,104 100% $8,757 100%

Net Sales by Geography

United States and Canada $6,909 62% $5,767 66%

Outside the United States and

Canada 4,195 38% 2,990 34%

$11,104 100% $8,757 100%

LEMAITRE VASCULAR, INC (Nasdaq: LMAT)

SELECTED NET SALES INFORMATION

(amounts in thousands)

(unaudited)

For the year ended

December 31, 2007 December 31, 2006

$ % $ %

Net Sales by Product Category:

Endovascular & Dialysis $14,166 34% $9,833 28%

Vascular 23,397 57% 20,992 61%

General Surgery 3,883 9% 3,803 11%

Total net sales $41,446 100% $34,628 100%

Net Sales by Geography

United States and Canada $25,141 61% $22,362 65%

Outside the United States and

Canada 16,305 39% 12,266 35%

$41,446 100% $34,628 100%

LEMAITRE VASCULAR, INC (Nasdaq: LMAT)

NON-GAAP FINANCIAL MEASURES

(amounts in thousands)

(unaudited) For the three months For the year

ended ended

December 31, 2007 December 31, 2007

Reconciliation between GAAP and

Non-GAAP operating loss:

Operating loss as reported ($1,317) ($4,283)

Purchased research and

development 373 373

Inventory write-down 105 105

Restructuring charges (credit) (17) 1,042

Impairment 0 7

Adjusted operating loss ($856) ($2,756)

ions, bought out our Italian distributor, launched four next- generation products and ramped up our sales force. In 2007, our sales became more endovascular (now 34%), more international (39%), more direct-to-hospital (90%) and more implantable (23%.) In 2008, we look forward to integrating our recent acquisitions and completing the launches of our TT Tortuous Tracker Stent Graft Delivery System as well as our EndoFit Uniform TopStent. Our compounded annual sales growth rate was 19% during the 2002-2007 period."

The Company reported a net loss of $1,178,000, or $0.08 per diluted share, for Q4 2007 compared to a net loss of $674,000, or $0.05 per diluted share, for Q4 2006. The 2007 net loss was $2,934,000, or $0.19 per diluted share, compared with the 2006 net loss of $1,172,000, or $0.15 per diluted share. The Q4 2007 operating loss was $1,317,000, compared to an operating loss of $433,000 for Q4 2006. The 2007 operating loss was $4,283,000 compared to an operating loss of $679,000 for 2006.

In 2007, the Company recorded $1.5 million of extraordinary charges. These included restructuring and impairment charges of $1,049,000 primarily from the Company's buyout of its Italian and Irish distributors, $373,000 of purchased R&D (non-cash), and the $105,000 Biomateriali OEM inventory write-down (non- cash). Excluding these three specific items, the non-GAAP operating loss for Q4 and 2007 would have been $856,000 and $2,756,000 respectively.

Sales and marketing expenses for 2007 increased 28% to $19,443,000 from $15,183,000 in 2006. The increase was primarily a result of a larger sales force. The Company ended 2007 with 57 sales representatives, compared to 47 at the end of 2006.

For 2007, general and administrative expenses increased 34% to $9,534,000. This increase was primarily the result of the higher costs associated with being a publicly-traded company for 12 months in 2007 versus 2 1/2 months in 2006.

R&D expenses, excluding purchased R&D, increased 39% to $4,591,000 in 2007, compared to $3,301,000 in 2006. The Company launched four products in 2007, including the Pruitt F3 Carotid Shunt (Q1), the Flexcel II Carotid Shunt (Q3), the TT Tortuous Tracker Delivery System (Q4) and the Endofit Uniform TopStent (Q4).

Business Outlook

The Company expects 2008 net sales between $47 million and $48 million. In addition, the Company expects its 2008 operating loss to be comparable to the $4.3 million operating loss posted in 2007. The Company's expectations for future financial performance do not include the impact of any potential acquisitions.

Conference Call Reminder

Management will conduct a conference call at 5:00 p.m. EST today to review the Company's financial results and discuss its business outlook for 2008. The conference call will be broadcast live over the internet. Individuals who are interested in listening to the webcast should log on to the Company's website at http://www.lemaitre.com/investor. The conference call may also be accessed by dialing 866-831-6267 (1-617-213-8857 for international callers) using passcode: 70767653. For interested individuals unable to join the live conference call, a replay will be available on the Company's website.

About LeMaitre Vascular

LeMaitre Vascular is a provider of devices for the treatment of peripheral vascular disease. We develop, manufacture and market disposable and implantable vascular devices to address the needs of vascular surgeons. The Company's devices are used to treat peripheral vascular disease, a condition that we estimate affects more than 20 million people worldwide.

Well-known to vascular surgeons, the Company's diversified product portfolio consists of brand name devices that are used in arteries and veins outside of the heart including the Expandable LeMaitre Valvulotome and the Pruitt-Inahara Carotid Shunt. Recent acquisitions include EndoMed, a manufacturer of endovascular stent grafts, and Biomateriali, a manufacturer of vascular grafts.

LeMaitre and the LeMaitre Vascular logo are trademarks of LeMaitre Vascular, Inc., registered in the U.S. and other countries. This press release contains trademarks and trade names of the Company and other third parties, which are the properties of their respective owners.

For more information about the Company, please visit http://www.lemaitre.com.

Use of Non-GAAP Financial Measures

LeMaitre Vascular management believes that in order to properly understand the Company's short-term and long-term financial trends, investors may wish to consider the impact of certain non-cash or non-recurring items, when used as a supplement to financial performance measures in accordance with GAAP. These items result from facts and circumstances that vary in frequency and/or impact on continuing operations. In addition, management uses results of operations before such items to evaluate the operational performance of the company and as a basis for strategic planning. Investors should consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures in accordance with GAAP. In addition to the description provided below, reconciliation of GAAP to non-GAAP results is provided in the financial statement tables included in this press release.

In this press release, the Company has reported a non-GAAP measure which excludes certain non-recurring expenses related to restructuring and to acquisitions. During 2007, the Company elected to terminate its exclusive distributors in Italy and Ireland prior to the expiration of their contracts and entered into separation agreements. The Company incurred charges of $1,042,000 in connection with these transactions. In Q4 2007, the Company acquired certain assets related to an endovascular device and incurred a non- cash charge for purchased R&D of $373,000, and wrote down $105,000 of OEM inventory acquired in the Biomateriali acquisition.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding the Company's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Specifically, statements regarding the Company's financial guidance for 2008, the integration of its 2007 acquisitions, and the launch of its TT Tortuous Tracker Delivery System and EndoFit Uniform TopStent are forward-looking statements involving risks and uncertainties. The Company's fourth quarter 2007 and fiscal year 2007 financial results, as discussed in this release, are preliminary and unaudited, and subject to adjustment. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results predicted. These risks and uncertainties include, but are not limited to, risks related to product demand and market acceptance of the Company's products; the significant competition the Company faces from other companies, technologies, and alternative medical procedures; the Company's ability to realize the anticipated benefits of its acquisitions; the Company's ability to effectively expand its sales force; the possibility that the Company's new products may fail to provide the desired safety and efficacy or may not be accepted by the market for other reasons; the Company's ability to expand its product offerings through internal development or acquisition; disruption at either of the Company's two manufacturing facilities; the general uncertainty related to seeking regulatory approvals for the Company's products, particularly in the United States; potential claims of third parties that the Company's products infringe their intellectual property rights; and the risks and uncertainties included under the heading "Risk Factors" in our most recent Annual Report on Form 10- K, as updated by our most recent quarterly report on Form 10-Q and other periodic filings with the SEC, all of which are available on the Company's investor relations website at http://www.lemaitre.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

Financial Statements

LEMAITRE VASCULAR, INC (Nasdaq: LMAT)

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

(amounts in thousands, except per share amounts)

For the three months ended

December 31, 2007 December 31, 2006

(unaudited)

Net sales $11,104 $8,757

Cost of sales 2,961 2,162

Gross profit 8,143 6,595

Operating expenses:

Sales and marketing 5,313 4,544

General and administrative 2,617 2,055

Research and development 1,174 715

Purchased research and development 373 -

Restructuring charges (credit) (17) 26

Impairment charge (credit) - (312)

Total operating expenses 9,460 7,028

Income (loss) from operations (1,317) (433)

Other income (expense):

Interest income (expense), net 244 278

Other (expense) income, net 8 4

Total other income (expense) 252 282

Income (loss) before income taxes (1,065) (151)

Provision for income taxes 113 523

Net income (loss) $(1,178) $(674)

Net income (loss) per share of common stock:

Basic $(0.08) $(0.05)

Diluted $(0.08) $(0.05)

Weighted average shares outstanding 15,465 13,876

Diluted weighted average shares

outstanding 15,465 13,876

LEMAITRE VASCULAR, INC (Nasdaq: LMAT)

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

(amounts in thousands, except per share amounts)

For the year ended

December 31, 2007 December 31, 2006

(unaudited)

Net sales $41,446 $34,628

Cost of sales 10,739 9,367

Gross profit 30,707 25,261

Operating expenses:

Sales and marketing 19,443 15,183

General and administrative 9,534 7,105

Research and development 4,591 3,301

Purchased research and development 373 -

Restructuring charges (credit) 1,042 257

Impairment charge (credit) 7 94

Total operating expenses 34,990 25,940

Income (loss) from operations (4,283) (679)

Other income (expense):

Interest income (expense), net 1,298 3

Other (expense) income, net 283 156

Total other income (expense) 1,581 159

Income (loss) before income taxes (2,702) (520)

Provision for income taxes 232 652

Net income (loss) $(2,934) $(1,172)

Net income (loss) per share of common

stock:

Basic $(0.19) $(0.15)

Diluted $(0.19) $(0.15)

Weighted average shares outstanding 15,398 9,904

Diluted weighted average shares

outstanding 15,398 9,904

LEMAITRE VASCULAR, INC (Nasdaq: LMAT)

CONDENSED CONSOLIDATED BALANCE SHEETS

(amounts in thousands)

December 31, 2007 December 31, 2006

(unaudited)

Assets

Current assets:

Cash and cash equivalents $6,691 $15,391

Marketable securities 16,198 15,417

Accounts receivable, net 7,020 5,060

Inventories 9,589 6,081

Other current assets 2,562 1,692

Total current assets 42,060 43,641

Property and equipment, net 2,891 2,389

Goodwill 10,942 8,853

Other intangibles, net 3,886 1,930

Other assets 1,372 150

Total assets $61,151 $56,963

Liabilities and Stockholders' Equity

Current liabilities:

Accounts payable $2,565 $818

Accrued expenses 6,661 4,528

Revolving line of credit 262 -

Acquisition-related obligations 851 -

Current portion of capital leases - 32

Total current liabilities 10,339 5,378

Long-term debt, net of current portion 42 -

Deferred tax liabilities 996 833

Other long-term liabilities 1,188 53


'/>"/>

SOURCE LeMaitre Vascular, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. LeMaitre Vascular, Inc. Schedules Fourth Quarter Results and Conference Call
2. LeMaitre Vascular Launches Next-Generation Stent Graft Delivery System
3. LeMaitre Vascular to Participate at Canaccord Adams Inaugural Cardiovascular Conference
4. LeMaitre Vascular Reports Q3 2007 Revenue of $10.1 Million, a 19% Increase
5. LeMaitre Vascular to Participate at CIBC 18th Annual Healthcare Conference
6. LeMaitre Vascular to Start Italian Sales Force
7. Led by Cardiovascular Applications, Double Digit Growth Expected for Catheter Sales
8. Randy Jackson and the American Heart Association Educate Minneapolis Area about the Connection between Type 2 Diabetes and Cardiovascular Disease
9. Randy Jackson and the American Heart Association Educate Cincinnati Area Residents about the Connection between Type 2 Diabetes and Cardiovascular Disease
10. Curry Ingredient May Cut Cardiovascular Risks
11. Overweight Hispanic children shown to have vascular inflammation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... 10, 2016 , ... Western University of Health Sciences and ... developmentally disabled in the Coachella Valley. , The two entities, through an expanded ... Highway 111, Suite 100-B, in Rancho Mirage, California. The new site has 11 ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... (VRI) within Healthcare, recently partnered with Heart City Health Center to ... nearly 23 years, Heart City Health Center has provided the Elkhart community with ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... master charity program created to assist the local community. Pledging to select a ... and nonprofit organizations in the area. Their goal is to bring community awareness ...
(Date:2/10/2016)... ... 10, 2016 , ... Dr. Peyman Ghasri, skin doctor ... variety of comprehensive procedures for facial enhancement. The treatments now available at Castle ... and nasal reshaping. , As a result, patients can improve virtually every ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... San Diego, will bring together more than 200 of the country’s top healthcare ... the future. , “The true benefit of the Forum is the provider-centric perspective, ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... PRINCETON, New Jersey and OR AKIVA, ... Regentis Biomaterials Ltd., a leader ... of its Series D investment round on February 5, ... Haisco Pharmaceutical Group ("Haisco"), a leading Chinese pharmaceutical ... Medica Partners, SCP Vitalife Partners, Generali Financial Holdings and ...
(Date:2/10/2016)... SAN DIEGO , Feb. 10, 2016 ALSP, ... Hack , MD as Consultant for Medical Affairs in preparation ... Michael Pierschbacher , PhD, CEO, stated, "We are ... team. We look forward to working with an individual of ... (TBI). We look forward to drawing deeply on his broad ...
(Date:2/10/2016)... , February 10, 2016 ... market research report "Pharmaceutical Packaging Equipment Market by Package ... & Serialization), by Product Type (Tablet, Powder, Cream, Syrup, ... by MarketsandMarkets, studies the global market during the forecast period ... grow at a CAGR of 6.9% during the forecast ...
Breaking Medicine Technology: